{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T14:12:39Z","timestamp":1795011159111,"version":"4.9.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill &amp; Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.vaccine.2022.12.037","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:41:17Z","timestamp":1696945277000},"page":"S76-S94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S2","title":["Vaccine value profile for Shigella"],"prefix":"10.1016","volume":"41","author":[{"given":"William P.","family":"Hausdorff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"IV","given":"John D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoun H.","family":"Bagamian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Louis","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Sawe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Scheele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawsar","family":"Talaat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte K.","family":"Giersing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.12.037_b0005","doi-asserted-by":"crossref","unstructured":"GBD 2016 Diarrhoeal Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis 2018;18:1211\u201328. https:\/\/doi.org\/10.1016\/S1473-3099(18)30362-1.","DOI":"10.1016\/S1473-3099(18)30362-1"},{"key":"10.1016\/j.vaccine.2022.12.037_b9000","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/infdis\/159.6.1126","article-title":"Inoculum size in shigellosis and implications for expected mode of transmission","volume":"159","author":"DuPont","year":"1989","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0015","first-page":"8","article-title":"A Brief History of Shigella","author":"Lampel","year":"2018","journal-title":"EcoSal Plus"},{"key":"10.1016\/j.vaccine.2022.12.037_b0020","doi-asserted-by":"crossref","first-page":"e1319","DOI":"10.1016\/S2214-109X(18)30351-6","article-title":"Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study","volume":"6","author":"Rogawski","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0025","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2214-109X(19)30541-8","article-title":"Diarrhoeal disease and subsequent risk of death in infants and children residing in low-income and middle-income countries: analysis of the GEMS case-control study and 12-month GEMS-1A follow-on study","volume":"8","author":"Levine","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0030","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1056\/NEJM197411282912223","article-title":"Letter: Shigella enteritis venereally transmitted","volume":"291","author":"Dritz","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.12.037_b0035","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1016\/j.vaccine.2021.05.086","article-title":"Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection","volume":"39","author":"Butkeviciute","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0040","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S1473-3099(18)30475-4","article-title":"Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990\u20132016","volume":"18","author":"Khalil","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0045","doi-asserted-by":"crossref","unstructured":"Colston JM, Zaitchik BF, Badr HS, Burnett E, Ali SA, Rayamajhi A, et al. Associations Between Eight Earth Observation-Derived Climate Variables and Enteropathogen Infection: An Independent Participant Data Meta-Analysis of Surveillance Studies With Broad Spectrum Nucleic Acid Diagnostics. GeoHealth 2022;6:e2021GH000452. https:\/\/doi.org\/10.1029\/2021GH000452.","DOI":"10.1029\/2021GH000452"},{"key":"10.1016\/j.vaccine.2022.12.037_b0050","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.1962.03050520005002","article-title":"Epidemiologic and sociologic features of a large urban outbreak of shigellosis","volume":"182","author":"Mosley","year":"1962","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.12.037_b0055","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(20)30114-8","article-title":"Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000\u201317: analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Local Burden of Disease Diarrhoea Collaborators","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2022.12.037_b0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2105\/AJPH.32.5.487","article-title":"The house fly as a vector of food poisoning organisms in food producing establishments","volume":"32","author":"Ostrolenk","year":"1942","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/21645515.2019.1640427","article-title":"Functional antibodies as immunological endpoints to evaluate protective immunity against Shigella","volume":"16","author":"Ndungo","year":"2020","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2022.12.037_b0070","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/infdis\/jiaa031","article-title":"Protection From Natural Immunity Against Enteric Infections and Etiology-Specific Diarrhea in a Longitudinal Birth Cohort","volume":"222","author":"Rogawski McQuade","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0075","series-title":"Approved Lists of Bacterial Names (Amended)","year":"1989"},{"key":"10.1016\/j.vaccine.2022.12.037_b0080","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s42770-021-00573-5","article-title":"Historical, current, and emerging tools for identification and serotyping of Shigella","volume":"52","author":"Halimeh","year":"2021","journal-title":"Braz J Microbiol Publ Braz Soc Microbiol"},{"key":"10.1016\/j.vaccine.2022.12.037_b0085","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/cid\/ciu468","article-title":"Shigella isolates from the global enteric multicenter study inform vaccine development","volume":"59","author":"Livio","year":"2014","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2022.12.037_b0090","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrmicro1662","article-title":"Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road","volume":"5","author":"Levine","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2022.12.037_b0095","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0100","doi-asserted-by":"crossref","first-page":"e1011","DOI":"10.1093\/cid\/ciab062","article-title":"Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework","volume":"73","author":"Vekemans","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0105","unstructured":"Centers for Disease Control and Prevention (U.S.), National Center for Emerging Zoonotic and Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. Antibiotic Resistance Coordination and Strategy Unit ., editors. Antibiotic resistance threats in the United States, 2019 2019."},{"key":"10.1016\/j.vaccine.2022.12.037_b0110","first-page":"6630272","article-title":"Multidrug-Resistant Shigellosis among Children Aged below Five Years with Diarrhea at Banadir Hospital in Mogadishu, Somalia","volume":"2021","author":"Ali Nor","year":"2021","journal-title":"Can J Infect Dis Med Microbiol J Can Mal Infect Microbiol Medicale"},{"key":"10.1016\/j.vaccine.2022.12.037_b0115","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/cid\/ciaa363","article-title":"Clinical Outcomes of Drug-resistant Shigellosis Treated With Azithromycin in Bangladesh","volume":"72","author":"Houpt","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2022.12.037_b0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.12.037_b0125","doi-asserted-by":"crossref","first-page":"e0008520","DOI":"10.1371\/journal.pntd.0008520","article-title":"Incidence and etiology of clinically-attended, antibiotic-treated diarrhea among children under five years of age in low- and middle-income countries: Evidence from the Global Enteric Multicenter Study","volume":"14","author":"Lewnard","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0130","doi-asserted-by":"crossref","first-page":"e058740","DOI":"10.1136\/bmjopen-2021-058740","article-title":"Antibiotic use attributable to specific aetiologies of diarrhoea in children under 2 years of age in low-resource settings: a secondary analysis of the MAL-ED birth cohort","volume":"12","author":"Brennhofer","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2022.12.037_b0135","first-page":"451","article-title":"The Aberdeen Epidemic of Milk-borne Bacillary Dysentery, March to May, 1919","volume":"21","author":"Kinloch","year":"1923","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2022.12.037_b0140","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/infdis\/81.1.68","article-title":"Field studies in bacillary dysentery in U.S. military personnel and civilians in North Africa and Italy; the epidemic of bacillary dysentery in the Atlantic Base Section, French Morocco, 1943","volume":"81","author":"Stock","year":"1947","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0145","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(95)90338-0","article-title":"Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994?","volume":"345","author":"Goma Epidemiology Group","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.12.037_b0150","doi-asserted-by":"crossref","first-page":"S764","DOI":"10.1093\/infdis\/jiab358","article-title":"Assessment of Vaccine Herd Protection: Lessons Learned From Cholera and Typhoid Vaccine Trials","volume":"224","author":"Deen","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0155","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.1016\/j.vaccine.2019.02.061","article-title":"Implications and measurement of herd protection (indirect effects) for enteric vaccine development","volume":"37","author":"Wierzba","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2022.100218","article-title":"Could a Shigella vaccine impact long-term health outcomes?: Summary report of an expert meeting to inform a Shigella vaccine public health value proposition, March 24 and 29, 2021","volume":"12","author":"Bagamian","year":"2022","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2022.12.037_b0165","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1016\/S2214-109X(18)30483-2","article-title":"Burden of enterotoxigenic Escherichia coli and shigella non-fatal diarrhoeal infections in 79 low-income and lower middle-income countries: a modelling analysis","volume":"7","author":"Anderson","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0170","first-page":"154","article-title":"Arthritis and intestinal disease","volume":"8","author":"Haslock","year":"1974","journal-title":"J R Coll Physicians Lond"},{"key":"10.1016\/j.vaccine.2022.12.037_b0175","first-page":"405","article-title":"Postdysenteric Reiter\u2019s syndrome","volume":"126","author":"Lehman","year":"1977","journal-title":"West J Med"},{"key":"10.1016\/j.vaccine.2022.12.037_b0180","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/acsinfecdis.0c00831","article-title":"Modeling Enteropathy or Diarrhea with the Top Bacterial and Protozoal Pathogens: Differential Determinants of Outcomes","volume":"7","author":"Guerrant","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0185","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(16)31529-X","article-title":"Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study","volume":"388","author":"Liu","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2022.12.037_b0190","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1473-3099(14)70808-4","article-title":"Development and assessment of molecular diagnostic tests for 15 enteropathogens causing childhood diarrhoea: a multicentre study","volume":"14","author":"Liu","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0195","doi-asserted-by":"crossref","first-page":"e02455","DOI":"10.1128\/JCM.02455-20","article-title":"Evaluation of Molecular Serotyping Assays for Shigella flexneri Directly on Stool Samples","volume":"59","author":"Liu","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2022.12.037_b0200","doi-asserted-by":"crossref","first-page":"e0170321","DOI":"10.1128\/JCM.01703-21","article-title":"Characterization of Enteric Disease in Children by Use of a Low-Cost Specimen Preservation Method","volume":"59","author":"Debes","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2022.12.037_b0205","unstructured":"World Health Organization. WHO preferred product characteristics for vaccines against Shigella. Geneva: 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240036741."},{"key":"10.1016\/j.vaccine.2022.12.037_b0210","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(98)07499-6","article-title":"Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol","volume":"353","author":"Ahmed","year":"1999","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.vaccine.2022.12.037_b0215","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S2214-109X(17)30490-4","article-title":"Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Bangladesh: a cluster randomised controlled trial","volume":"6","author":"Luby","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0220","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.1016\/S2214-109X(18)30005-6","article-title":"Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Kenya: a cluster-randomised controlled trial","volume":"6","author":"Null","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0225","series-title":"Clean Water and Sanitation","author":"Ritchie","year":"2021"},{"key":"10.1016\/j.vaccine.2022.12.037_b0230","doi-asserted-by":"crossref","first-page":"e1235","DOI":"10.1016\/S2214-109X(17)30392-3","article-title":"Identification and management of Shigella infection in children with diarrhoea: a systematic review and meta-analysis","volume":"5","author":"Tickell","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0235","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1080\/20469047.2017.1409454","article-title":"Guidelines for the treatment of dysentery (shigellosis): a systematic review of the evidence","volume":"38","author":"Williams","year":"2018","journal-title":"Paediatr Int Child Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0240","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/tmi.13051","article-title":"Impact of drinking water, sanitation and handwashing with soap on childhood diarrhoeal disease: updated meta-analysis and meta-regression","volume":"23","author":"Wolf","year":"2018","journal-title":"Trop Med Int Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0245","doi-asserted-by":"crossref","first-page":"e2280","DOI":"10.1371\/journal.pntd.0002280","article-title":"Housefly Population Density Correlates with Shigellosis among Children in Mirzapur, Bangladesh: A Time Series Analysis","volume":"7","author":"Farag","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0250","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/clinids\/13.4.688","article-title":"Houseflies (Musca domestica) as mechanical vectors of shigellosis","volume":"13","author":"Levine","year":"1991","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0255","first-page":"CD006784","article-title":"Antibiotic therapy for Shigella dysentery","author":"Christopher","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2022.12.037_b0260","unstructured":"Decreased Susceptibility to Azithromycin in Clinical Shigella Isolates Associated with HIV and Sexually Transmitted Bacterial Diseases, Minnesota, USA, 2012-2015 - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/32186495\/ (accessed March 31, 2022)."},{"key":"10.1016\/j.vaccine.2022.12.037_b0265","doi-asserted-by":"crossref","first-page":"e1309","DOI":"10.1016\/S2214-109X(18)30349-8","article-title":"Use of quantitative molecular diagnostic methods to assess the aetiology, burden, and clinical characteristics of diarrhoea in children in low-resource settings: a reanalysis of the MAL-ED cohort study","volume":"6","author":"Platts-Mills","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0270","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000475","article-title":"Recent insights into Shigella","volume":"31","author":"Baker","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0275","unstructured":"Wellcome Trust. Vaccines to tackle drug resistant infections: An evaluation of R&D opportunities 2022. https:\/\/vaccinesforamr.org\/wp-content\/uploads\/2018\/09\/Vaccines_for_AMR.pdf (accessed March 1, 2022)."},{"key":"10.1016\/j.vaccine.2022.12.037_b0280","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1016\/j.vaccine.2017.07.036","article-title":"Global burden of diarrheal diseases among children in developing countries: Incidence, etiology, and insights from new molecular diagnostic techniques","volume":"35","author":"Kotloff","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0285","unstructured":"Bill and Melinda Gates Foundation. Intervention Target Product Profile for Shigella, version 2.7. Seattle: 2021."},{"key":"10.1016\/j.vaccine.2022.12.037_b0290","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.vaccine.2008.03.008","article-title":"Development of a travelers\u2019 diarrhea vaccine for the military: How much is an ounce of prevention really worth?","volume":"26","author":"Riddle","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0295","unstructured":"Coherent Market Insights. Shigella Vaccines Market Size, Trends And Forecast To 2028 n.d. https:\/\/www.coherentmarketinsights.com\/market-insight\/shigella-vaccines-market-1110 (accessed October 14, 2022)."},{"key":"10.1016\/j.vaccine.2022.12.037_b0300","article-title":"Full Value of Vaccine Assessment (FVVA) for Shigella vaccines: 2020 WHO Product Development for Vaccines Advisory Committee (PDVAC)","volume":"3","author":"World Health Organization","year":"2020","journal-title":"Virtual Consultation"},{"key":"10.1016\/j.vaccine.2022.12.037_b0305","doi-asserted-by":"crossref","first-page":"e0012221","DOI":"10.1128\/mSphere.00122-21","article-title":"Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei","volume":"6","author":"Clarkson","year":"2021","journal-title":"MSphere"},{"key":"10.1016\/j.vaccine.2022.12.037_b0310","doi-asserted-by":"crossref","first-page":"e00988","DOI":"10.1128\/mSphere.00988-19","article-title":"Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G","volume":"5","author":"Clarkson","year":"2020","journal-title":"MSphere"},{"key":"10.1016\/j.vaccine.2022.12.037_b0315","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1080\/21645515.2019.1606971","article-title":"Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis","volume":"15","author":"Cohen","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2022.12.037_b0320","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1016\/j.vaccine.2017.05.005","article-title":"Correlates of protection for enteric vaccines","volume":"35","author":"Holmgren","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0325","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1093\/cid\/ciz909","article-title":"Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays","volume":"69","author":"Kaminski","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2022.12.037_b0330","doi-asserted-by":"crossref","first-page":"e00260","DOI":"10.1128\/mSphere.00260-18","article-title":"A Novel Shigella Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge","volume":"3","author":"Ndungo","year":"2018","journal-title":"MSphere"},{"key":"10.1016\/j.vaccine.2022.12.037_b0335","doi-asserted-by":"crossref","first-page":"e00412","DOI":"10.1128\/CVI.00412-16","article-title":"Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study","volume":"24","author":"Shimanovich","year":"2017","journal-title":"Clin Vaccine Immunol CVI"},{"key":"10.1016\/j.vaccine.2022.12.037_b0340","first-page":"40","article-title":"Systems approach to define humoral correlates of immunity to Shigella","author":"Bernshtein","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2022.12.037_b0345","doi-asserted-by":"crossref","first-page":"e20201116","DOI":"10.1084\/jem.20201116","article-title":"Vi-specific serological correlates of protection for typhoid fever","volume":"218","author":"Jin","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2022.12.037_b0350","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/vaccines10040548","article-title":"From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine\u2019s Refinement and Evolution","volume":"10","author":"Turbyfill","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.12.037_b0355","doi-asserted-by":"crossref","first-page":"S829","DOI":"10.1093\/infdis\/jiab395","article-title":"Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella sonnei Vaccine Candidate, in Bangladeshi Adults and Children","volume":"224","author":"Sarker","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-020-0180-y","article-title":"A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice","volume":"5","author":"Medeiros","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2022.12.037_b0365","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/microorganisms9071382","article-title":"Vaccines for Protecting Infants from Bacterial Causes of Diarrheal Disease","volume":"9","author":"Walker","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.vaccine.2022.12.037_b0370","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/jcm.29.2.386-389.1991","article-title":"Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis","volume":"29","author":"Cohen","year":"1991","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2022.12.037_b0375","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/infdis\/157.5.1068","article-title":"Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population","volume":"157","author":"Cohen","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0380","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1016\/j.vaccine.2017.07.070","article-title":"Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice","volume":"35","author":"Farzam","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0385","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2009.12.050","article-title":"Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1\u20134-year-old Israeli children","volume":"28","author":"Passwell","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0390","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/vaccines10040489","article-title":"Pivotal Shigella Vaccine Efficacy Trials-Study Design Considerations from a Shigella Vaccine Trial Design Working Group","volume":"10","author":"Pavlinac","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.12.037_b0395","doi-asserted-by":"crossref","first-page":"e0008536","DOI":"10.1371\/journal.pntd.0008536","article-title":"Epidemiology of Shigella infections and diarrhea in the first two years of life using culture-independent diagnostics in 8 low-resource settings","volume":"14","author":"Rogawski McQuade","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0400","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1016\/j.vaccine.2019.03.036","article-title":"How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?","volume":"37","author":"Giersing","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0405","doi-asserted-by":"crossref","first-page":"S591","DOI":"10.1093\/cid\/ciz891","article-title":"Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints","volume":"69","author":"MacLennan","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2022.12.037_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103310","article-title":"Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection","volume":"66","author":"Talaat","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101076","article-title":"Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults","volume":"39","author":"Frenck","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0420","doi-asserted-by":"crossref","first-page":"70","DOI":"10.12688\/wellcomeopenres.12256.1","article-title":"A framework for Controlled Human Infection Model (CHIM) studies in Malawi: Report of a Wellcome Trust workshop on CHIM in Low Income Countries held in Blantyre","volume":"2","author":"Gordon","year":"2017","journal-title":"Malawi Wellcome Open Res"},{"key":"10.1016\/j.vaccine.2022.12.037_b0425","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.16432.1","article-title":"Engagement of ethics and regulatory authorities on human infection studies: Proceedings of an engagement workshop in Zambia","author":"Kunda-Ng\u2019andu","year":"2021","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.vaccine.2022.12.037_b0430","article-title":"Human Challenge Trials for Vaccine Development: regulatory considerations","author":"World Health Organization","year":"2016","journal-title":"Expert Committee on Biological Standardization"},{"key":"10.1016\/j.vaccine.2022.12.037_b0435","article-title":"FDA approves vaccine to prevent cholera for travelers","author":"Food","year":"2020","journal-title":"FDA"},{"key":"10.1016\/j.vaccine.2022.12.037_b0440","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/1471-2458-12-276","article-title":"Systematic review of diarrhea duration and severity in children and adults in low- and middle-income countries","volume":"12","author":"Lamberti","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0445","doi-asserted-by":"crossref","first-page":"e0194325","DOI":"10.1371\/journal.pone.0194325","article-title":"Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score","volume":"13","author":"Porter","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2022.12.037_b0450","unstructured":"Vesikari Clinical Severity Scoring System Manual n.d. https:\/\/www.path.org\/resources\/vesikari-clinical-severity-scoring-system-manual\/ (accessed December 14, 2021)."},{"key":"10.1016\/j.vaccine.2022.12.037_b0455","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1016\/j.vaccine.2017.06.076","article-title":"Combination vaccine strategies to prevent enteric infections","volume":"35","author":"Walker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0460","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.vaccine.2014.11.049","article-title":"An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children","volume":"33","author":"Walker","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0465","first-page":"1039","article-title":"Update on vaccines for enteric pathogens","volume":"24","author":"Riddle","year":"2018","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0470","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1473-3099(20)30488-6","article-title":"Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study","volume":"21","author":"Cohen","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0475","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3390\/vaccines8040689","article-title":"Characterization of ShigETEC, a Novel Live Attenuated Combined Vaccine against Shigellae and ETEC","volume":"8","author":"Harutyunyan","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.12.037_b0480","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/vaccines10020340","article-title":"Evaluation of the Safety, Tolerability and Immunogenicity of ShigETEC, an Oral Live Attenuated Shigella-ETEC Vaccine in Placebo-Controlled Randomized Phase 1 Trial","volume":"10","author":"Girardi","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.12.037_b0485","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.vaccine.2009.11.001","article-title":"Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity","volume":"28","author":"Barnoy","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0490","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1016\/j.vaccine.2018.06.063","article-title":"A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei","volume":"36","author":"Frenck","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0495","unstructured":"ShigOraVax. EVI n.d. https:\/\/www.euvaccine.eu\/diarrheal-diseases\/ShigOraVax (accessed March 31, 2022)."},{"key":"10.1016\/j.vaccine.2022.12.037_b0500","article-title":"EVI and Hilleman Laboratories announce partnership to assess a new vaccine against Shigella","author":"Evi","year":"2019","journal-title":"EVI"},{"key":"10.1016\/j.vaccine.2022.12.037_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2019.100024","article-title":"Potential impact and cost-effectiveness of future ETEC and Shigella vaccines in 79 low- and lower middle-income countries","volume":"2","author":"Anderson","year":"2019","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2022.12.037_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2019.100043","article-title":"Heterogeneity in potential impact and cost-effectiveness of ETEC and Shigella vaccination in four sub-Saharan African countries","volume":"3","author":"Anderson","year":"2019","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2022.12.037_b0515","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.vaccine.2020.01.075","article-title":"Application of a cost-effectiveness analysis of pathogen-specific vaccines against gastroenteritis to a military population in a developing country setting","volume":"38","author":"Ballard","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0520","doi-asserted-by":"crossref","first-page":"S848","DOI":"10.1093\/infdis\/jiab434","article-title":"Pathogens Associated With Linear Growth Faltering in Children With Diarrhea and Impact of Antibiotic Treatment: The Global Enteric Multicenter Study","volume":"224","author":"Nasrin","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0525","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1093\/cid\/ciaa1938","article-title":"Diarrheal Pathogens Associated With Growth and Neurodevelopment","volume":"73","author":"Donowitz","year":"2021","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2022.12.037_b0530","series-title":"Principles and considerations for adding a vaccine to a national immunization programme: from decision to implementation and monitoring","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.vaccine.2022.12.037_b0535","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1016\/j.vaccine.2004.11.044","article-title":"Policymakers\u2019 views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia","volume":"23","author":"DeRoeck","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0540","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1016\/j.vaccine.2019.01.031","article-title":"Capturing the true burden of Shigella and ETEC: The way forward","volume":"37","author":"Khalil","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.12.037_b0545","unstructured":"World Health Organization. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae type 1. 2005. https:\/\/www.who.int\/publications\/i\/item\/9241592330."},{"key":"10.1016\/j.vaccine.2022.12.037_b0550","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1080\/21645515.2015.1044180","article-title":"The value of childhood combination vaccines: From beliefs to evidence","volume":"11","author":"Maman","year":"2015","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2022.12.037_b0555","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41579-020-00506-3","article-title":"The role of vaccines in combatting antimicrobial resistance","volume":"19","author":"Micoli","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2022.12.037_b0560","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.12688\/f1000research.20100.1","article-title":"Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance\u2019s 2018 Vaccine Investment Strategy: report from an expert survey","volume":"8","author":"Malarski","year":"2019","journal-title":"F1000Research"},{"key":"10.1016\/j.vaccine.2022.12.037_b0565","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/S2214-109X(19)30456-5","article-title":"Heterogeneity in enterotoxigenic Escherichia coli and shigella infections in children under 5 years of age from 11 African countries: a subnational approach quantifying risk, mortality, morbidity, and stunting","volume":"8","author":"Bagamian","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b0570","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/cid\/ciz005","article-title":"Co-circulation of Multidrug-resistant Shigella Among Men Who Have Sex With Men in Australia","volume":"69","author":"Ingle","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.12.037_b0575","doi-asserted-by":"crossref","unstructured":"Gastroenteritis in Men Who Have Sex With Men in Seattle, Washington, 2017\u20132018 | Clinical Infectious Diseases | Oxford Academic n.d. https:\/\/academic.oup.com\/cid\/article\/71\/1\/109\/5588835?login=true (accessed March 31, 2022).","DOI":"10.1093\/cid\/ciz783"},{"key":"10.1016\/j.vaccine.2022.12.037_b0580","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/vaccines10020282","article-title":"What Drives the Value of a Shigella Vaccine?","volume":"10","author":"Hausdorff","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.12.037_b0585","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/cid\/ciy877","article-title":"Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine","volume":"68","author":"Yousafzai","year":"2019","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2022.12.037_b90001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2023.100368","article-title":"Exploring Shigella vaccine priorities and preferences: Results from a mixed-methods study in low- and middle-income settings","volume":"15","author":"Fleming","year":"2023","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2022.12.037_b9005","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1016\/S2214-109X(23)00050-5","article-title":"Projecting the long-term economic benefits of reducing Shigella-attributable linear growth faltering with a potential vaccine: a modelling study","volume":"11","author":"Puett","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b9010","doi-asserted-by":"crossref","first-page":"e880","DOI":"10.1016\/S2214-109X(23)00192-4","article-title":"Potential impact and cost-effectiveness of Shigella vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: a modelling study","volume":"11","author":"Anderson","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2022.12.037_b9015","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.vaccine.2023.03.003","article-title":"Challenges and opportunities in developing a Shigella-containing combination vaccine for children in low- and middle-income countries: Report of an expert convening","volume":"41","author":"Riddle","year":"2023","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:29:41Z","timestamp":1786217381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22015626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":121,"alternative-id":["S0264410X22015626"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine value profile for Shigella","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}